Review
Published on 13 Dec 2022
Targeted therapy of RET fusion-positive non-small cell lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1033484
- 8,814 views
- 7 citations
Type at least 3 characters
1,724 articles
Articles
Correction
Published on 13 Dec 2022
Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1113289
- 720 views
Case Report
Published on 12 Dec 2022
Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1042525
- 1,787 views
- 1 citation
Case Report
Published on 12 Dec 2022
Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1086677
- 3,008 views
- 4 citations
Original Research
Published on 09 Dec 2022
RRBP1 depletion of bone metastatic cancer cells contributes to enhanced expression of the osteoblastic phenotype
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1005152
- 2,224 views
Case Report
Published on 08 Dec 2022
Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1024365
- 1,670 views
- 3 citations
Original Research
Published on 08 Dec 2022
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1052163
- 2,541 views
- 7 citations
Original Research
Published on 08 Dec 2022
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1066926
- 3,192 views
- 11 citations
Review
Published on 06 Dec 2022
The regulatory role of N6-methyladenosine RNA modification in gastric cancer: Molecular mechanisms and potential therapeutic targets
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1074307
- 3,019 views
- 8 citations
Original Research
Published on 05 Dec 2022
Effects of osteoblast-derived extracellular vesicles on aggressiveness, redox status and mitochondrial bioenergetics of MNNG/HOS osteosarcoma cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.983254
- 2,667 views
- 3 citations
Original Research
Published on 02 Dec 2022
WWOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.996820
- 2,843 views
- 3 citations
Systematic Review
Published on 01 Dec 2022
Cellular functions and molecular mechanisms of ubiquitination in osteosarcoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1072701
- 1,565 views
- 2 citations
Original Research
Published on 01 Dec 2022
Targeting H3K27me3 demethylase to inhibit Shh signaling and cholesterol metabolism in medulloblastoma growth
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1057147
- 1,907 views
- 1 citation
Original Research
Published on 30 Nov 2022
BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1011173
- 2,153 views
- 3 citations
Original Research
Published on 30 Nov 2022
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1021632
- 2,801 views
- 3 citations
Original Research
Published on 30 Nov 2022
Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2022.1055376
- 3,387 views
- 5 citations